Exact Sciences Corp ( (EXAS) ) has released its Q4 earnings. Here is a breakdown of the information Exact Sciences Corp presented to its investors.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Exact Sciences Corp. is a prominent player in the healthcare sector, specializing in cancer screening and diagnostic testing, with innovations like the Cologuard and Oncotype DX tests. In its latest earnings report, Exact Sciences revealed a strong financial performance for 2024, with a total revenue of $2.76 billion, marking a 10% increase from the previous year. The company continues to lead in cancer diagnostics, with a 14% rise in screening revenue and a slight increase in precision oncology revenue. Despite a significant net loss primarily due to impairment charges, the company’s adjusted EBITDA rose by $26 million to $75 million in the fourth quarter. Key highlights include the planned launch of three new cancer tests in 2025, which are expected to drive future growth. Looking ahead, Exact Sciences anticipates a continued upward trajectory in 2025, with projected revenue between $3.025 billion and $3.085 billion as it rolls out innovative cancer screening solutions.
